Developing An Alternative Way to Analyze NanoString Data by Shen, Shu
University of Kentucky 
UKnowledge 
Theses and Dissertations--Statistics Statistics 
2016 
Developing An Alternative Way to Analyze NanoString Data 
Shu Shen 
University of Kentucky, shu.shen@uky.edu 
Digital Object Identifier: http://dx.doi.org/10.13023/ETD.2016.385 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Shen, Shu, "Developing An Alternative Way to Analyze NanoString Data" (2016). Theses and 
Dissertations--Statistics. 20. 
https://uknowledge.uky.edu/statistics_etds/20 
This Doctoral Dissertation is brought to you for free and open access by the Statistics at UKnowledge. It has been 
accepted for inclusion in Theses and Dissertations--Statistics by an authorized administrator of UKnowledge. For 
more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained needed written permission statement(s) 
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine) which will be 
submitted to UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s thesis including all 
changes required by the advisory committee. The undersigned agree to abide by the statements 
above. 
Shu Shen, Student 
Dr. Arnold J.Stromberg, Major Professor 
Dr. Constance Wood, Director of Graduate Studies 
Developing An Alternative Way to Analyze NanoString Data
DISSERTATION
A dissertation submitted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy in the
College of Arts and Sciences
at the University of Kentucky
By
Shu Shen
Lexington, Kentucky
Director: Dr. Arnold J.Stromberg, Professor of Statistics
Lexington, Kentucky
2016
Copyright c© Shu Shen 2016
ABSTRACT OF DISSERTATION
Developing An Alternative Way to Analyze NanoString Data
Nanostring technology provides a new method to measure gene expressions. It’s more
sensitive than microarrays and able to do more gene measurements than RT-PCR with
similar sensitivity. This system produces counts for each target gene and tabulates
them. Counts can be normalized by using an Excel macro or nSolver before analysis.
Both methods rely on data normalization prior to statistical analysis to identify
differentially expressed genes. Alternatively, we propose to model gene expressions
as a function of positive controls and reference gene measurements. Simulations and
examples are used to compare this model with Nanostring normalization methods.
The results show that our model is more stable, efficient, and able to control false
positive proportions. In addition, we also derive asymptotic properties of a normalized
test of control versus treatment.
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Chapter 1 Introduction
1.1 Overview
The NanoString nCounter platform was developed by NanoString Technologies as a
new technology to do gene expression studies. Comparing to traditional microarray
and RT-PCR, besides the ability of dealing more samples without reducing sensibil-
ity, the system also shows excellent robustness and reproducibility( Malkov et al.,
2009; Veldman-Jones et al., 2015a; Veldman-Jones et al., 2015b). And it’s flexible,
fast and simple: researchers only need to add RNA samples to the platform and then
press the start button, the system will produce the gene expressions automatically.
This system is based on a novel digital molecular barcoding technology and all the
outcomes are counts. We refer to the counts as NanoString nCounter data.
1.2 Data Production
The NanoString nCounter platform produces data in three steps according to nCounter
Brochure(2015).
First step: Hybridization.
Each gene of interest is a target sequence and a corresponding capture probe and
reporter probe are used to detect the target. The capture probe has a biotin part
which is used to immobilize the sample and the reporter probe is bar coded for future
counting. The capture probes and reporter probes for all the target sequences are
hybridized to the sample which will create some tripartite structures: a target mRNA
bound to its capture and reporter probes.
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Second step: Sample processing.
This step is performed by the nCounter Prep Station: excess probes are removed and
hybridized probes are bound to the cartridge.
Third step: Count.
Sample cartridges are placed in the nCounter Digital Analyzer for automatic digital
counting. Barcodes are counted and tabulated for each target molecule. All the out-
puts are counts.
1.3 Data File
Tabulated output consists of three parts: file attributes, lane attributes and reporter
counts.
File attributes contains the basic information of the file, such as file name, ID, owner
and date while the lane attributes shows the information for each lane, such as lane
ID and binding density.
Reporter counts is the most important part of the table and it also consists of three
parts: positive control, negative control and endogenous, gene counts.
Different assay types have different numbers of positive controls and negative con-
trols. Take mRNA gene expression as an example. Under such a condition, 6 positive
controls and 8 negative controls are included. Each positive control is at one of the
following concentrations: 128 fm, 32 fm, 8 fm, 2 fm, 0.5 fm and 0.125 fm. This range
corresponds to most mRNA expression levels. The rest are endogenous genes. Be-
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sides genes we are interested in, there are genes called reference genes. Those genes
are pre-selected from a certain reference gene library provided by the company. They
are expected to be similar for all samples.
1.4 Data Normalization
In gene expression study, normalization is a common method(Vandesompele et al.,
2002; Bullard, 2010; Garmire, 2012). According to nCounter Expression Data Anal-
ysis Guide(2012), due to slight differences in data production, NanoString suggests
normalizing the data by using the internal controls before data analysis. Recently,
there are two ways to do the normalization. One is using an Excel macro and the
other is using a software called nSolver.
1.4.1 Using Excel worksheet
Here are three steps if normalization is performed by using Excel worksheet based
on nCounter Expression Data Analysis Guide(2012): positive control normalization,
reference gene normalization and assessing background.
Positive control normalization
This step normalizes all the variation related to the platform.
1. For each lane, compute the summation of all the positive controls.
2. Compute the average of all the summations from previous step.
3. Divide this average by each lane’s positive control summation to get that lane’s
positive control norm factor.
4. Multiply all the gene expressions in a lane by that lane’s positive control norm
3
factor to get the positive control normalized gene expressions.
Reference gene normalization
Reference genes are pre-selected genes which are supposed not to express vary be-
tween samples. This step is used to adjust all the genes to these consistent reference
genes. This step starts with the positive control normalized gene expressions.
1. For each lane, compute the geometric mean of the reference genes. The rea-
son for using geometric mean is reference genes are always expressed at difference
levels and geometric mean is less sensitive to the variation.
2. Compute the average of all the geometric means from previous step.
3. Divide this average by each lane’s reference gene geometric mean to get that lane’s
reference gene norm factor.
4. Multiply all the gene expressions in a lane by that lane’s reference gene norm
factor to get the reference gene normalized gene expressions.
Assessing background
Negative controls are probes for which no target is expected to be present and thus,
they can be used to estimate the background of the experiment. Several ways are in-
troduced to determine the background, such as mean of negative controls or mean plus
standard deviation of negative controls. Once the background threshold is decided,
subtract them from the gene expressions will complete the normalization process.
There are things to note when normalization is performed by using Excel worksheet.
For example, in the positive control normalization step, instead of using the summa-
tion of positive controls, the official user guide also lists average or geometric mean
of positive controls as alternative options.
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1.4.2 Using nSolver v1.1
nSolver v1.1 which is developed by NanoString, can be used to do normalization and
other analyses.
The first step is importing data and selecting the data type. Two kinds of files
can be imported through the main menu: RCC files and CodeSet RLF file.
After the raw data is imported, choose ‘Study’ from the drop down menu to start a
new study page. In this page, we are able to specify the properties for this study,
such as name, group, research area and description. Then select ‘Experiment’ from
the drop down menu to set up a new experiment to start the data analysis. As the
new page pops out, properties of the experiment can be specified.
Next step is adding samples. If different assay types of data are stored, select the
appropriate type from the left of the page will help to locate the data quickly. Then
select the ‘CodeSet’ from the navigation tree and all the samples will show up in the
table view. If here are some samples need to be excluded, select them and press the
‘Exclude Selected’ button, then these samples will become hidden. All samples visible
in the table view will be used for the experiment when the ‘Next’ button is pressed.
If anything need to be specified for the samples, we can also sample annotations.
Then the following step is selecting normalization type and parameters for the ex-
periment. Two normalization types are available: Positive Control Normalization
and CodeSet Content Normalization which is using the reference genes. nSolver v1.1
makes these two kinds of normalization optional: we can choose to use both or just
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one or even neither of them. Suppose we want to use both to normalize the raw data
and next we will select the normalization parameters.
For the positive control normalization, positive controls show up automatically in
a window view, but besides using them all, nSolver makes it possible to choose part
of them to compute the norm factor. And two options are provided for norm factor
computation: mean and geometric mean. Once this is decided, we should choose the
parameters for the CodeSet Content Normalization. Unlike the positive controls, if
the reference genes are not marked as ‘House Keeping’ in the raw data set, they will
not show up automatically. In this case, we have to pick those reference genes and
transfer them into the Normalization Codes window. Once again, both mean and
geometric mean can be used to compute the norm factor.
When everything is set, last two steps are to specify baseline data for creating fold
change estimates if ‘Build ratio’ is selected and to assign names to the fold change
data. Experiment results are listed in the left side of the window and they could be
exported in different formats.
1.4.3 Formulize the normalization process
In section 1.4.1 and 1.4.2, we showed how to do normalization step by step by using
Excel workflow and nSolver v1.1. In this section, we will formulize the positive con-
trol normalization and the reference gene normalization steps which are performed in
Excel workflow.
Denotation:
6
Suppose we have m samples. Denote positive controls as pij, negative controls as nij,
reference genes as rij and non-reference genes as gij for row/gene i and sample j.
Positive Control Normalization
Raw positive controls

p11 . . . p1m
...
. . .
...
p61 . . . p6m

1. Summation for the jth lane:
p.j = p1j + · · ·+ p6j, j = 1, ...,m
2. Average of all the summations:∑
j p.j
m
= p..
m
, p.. =
∑
ij pij
3. Norm factor for each lane:
p..
mp.j
, j = 1, ...,m
Suppose here are t non-reference genes and s reference genes, then the positive control
normalized gene expressions would be:

g11 × p..mp.1 . . . g1m ×
p..
mp.m
...
. . .
...
gt1 × p..mp.1 . . . gtm ×
p..
mp.m
r11 × p..mp.1 . . . r1m ×
p..
mp.m
...
. . .
...
rs1 × p..mp.1 . . . rsm ×
p..
mp.m

Reference Gene Normalization
1. Geometric mean of reference genes for the jth lane:
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p..
mp.j
× (∏si=1 rij) 1s , j = 1, ...,m
2. Average of all the geometric means:
p..
m2
∑m
j=1
rj
p.j
, where rj = (
∏s
i=1 rij)
1
s , j = 1, ...,m
3. Norm factor for each lane j:
p.j
mrj
∑m
j=1
rj
p.j
, j = 1, ...,m
Then the reference gene normalized gene expressions would be:

g11 × p..m2r1 ×
∑m
j=1
rj
p.j
. . . g1m × p..m2rm ×
∑m
j=1
rj
p.j
...
. . .
...
gt1 × p..m2r1 ×
∑m
j=1
rj
p.j
. . . gtm × p..m2rm ×
∑m
j=1
rj
p.j
r11 × p..m2r1 ×
∑m
j=1
rj
p.j
. . . r1m × p..m2rm ×
∑m
j=1
rj
p.j
...
. . .
...
rs1 × p..m2r1 ×
∑m
j=1
rj
p.j
. . . rsm × p..m2rm ×
∑m
j=1
rj
p.j

After these two steps of normalization, the original gene expression gij is transformed
to gij × p..m2rj ×
∑
j
rj
p.j
, where p.. =
∑
ij pij, rj = (
∏s
i=1 rij)
1
s , j = 1, ...,m
1.5 Summary
Normalization, which is introduced by NanoString, is used to correct the differences
caused by the data production steps. The above two ways are used to use to achieve
the goal: using Excel worksheet is more intuitive while using nSolver v1.1 is simpler
and faster.
One thing to note is nSolver v1.1 does not have “assessing background” step and
the reason for this is the company thinks there is no single appropriate algorithm to
estimate background and it is not necessarily applicable for all downstream analyses.
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Therefore if we normalize a raw data set by using both Excel and nSolver v1.1, we
will get different results. Even if we only apply the first two normalization steps and
choose the same normalization parameters for both methods, we will not expect the
exactly the same normalized data. This is because there are some minor differences
in the algorithm used by nSolver v1.1 such as the number of significant digits used
in the calculations. All of these reveals a problem of normalization: the normalized
data relies a lot on the parameters and method chosen by researchers which means
we cannot expect a consistent result.
Take a real data set for example. In this 2x2 design experiment, 12 cell samples
are used to measure the expressions of 236 genes. Table 1.1 lists the differences of
significant genes(p-value<0.05) for two kinds of normalized data: the first one is
normalized without background correction and the second one is normalized with
background correction. Both of them are done by using Excel Workflow.And from
this table, we could see the significant genes are not exactly the same based on these
two differently normalized data sets.
Table 1.1: This table shows the numbers of significant genes for overall ANOVA and
6 pairwise T-test comparisons
no background correction with background correction significant genes in common
overall 145 144 133
T-test 1 104 98 96
T-test 2 76 78 72
T-test 3 77 79 73
T-test 4 89 89 83
T-test 5 125 140 118
T-test 6 81 78 72
It’s possible that the differences of the normalized data are too minor to cause a huge
different in the results. But we don’t want the analysis to be affected by unstable
normalized data and this brings us an idea of looking for an alternative way to analyze
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the NanoString data without normalization. This new way should be more consistent
and reliable. In this case, building a model to pick up those differentially expressed
(DE) genes is a good way to proceed.
1.6 Methods
In the following study, we will focus on the simplest and also the most popular exper-
imental design, a two sample comparison: gene expressions are presented under two
different conditions, let’s say treatment and control. The usual way of doing analysis
is after normalization, a two sample t-test is performed for each gene. Then some
other rules are accordingly applied to the p-value list to identify DE genes, such as
False Discovery Rate (FDR) control or a fold change (FC) cutoff.
False Discovery Rate Control
Table 1.2: This table shows the definition of m hypothesis tests
H0 is True H1 is True Total
Declared significant V S R
Declared non-significant U T m-R
Total m0 m-m0 m
Based on definition Table 1.2, the proportion of false discoveries among the discoveries
is V
R
, and the false discovery rate is E(V
R
), where V
R
is defined to be 0 when R=0. And
we want to keep this value below a certain threshold. False discovery rate (FDR) con-
trol is a statistical method used in multiple hypothesis testing to correct for multiple
comparisons. It’s designed to control the expected proportion of incorrectly rejected
null hypotheses (“false discoveries”). In gene studies, it’s used to control the rate of
non DE genes among detected changes. In order to control FDR for multiple testing,
two general types of adjustment were developed: one is a single-step adjustment which
is accessing significance of all p-values with a single criterion and another one is step-
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down adjustment which is applying different criterion for each of the ordered p-values.
Single-step adjustment example
Bonferroni adjustment:
To keep the overall significant level still at α, use α
′
= α
m
as the significant level for
the individual tests. This adjustment is the most naive way to address the issue, but
it’s too conservative.
Step-down adjustment example
Benjamini- Hochberg procedure (Benjamini, Yoav and Hochberg, Yosef, 1995):
Consider multiple testing H1, ..., Hm and their corresponding p-values P1, ..., Pm.
1. Order p-values in an increasing order and denote them as P(1), ..., P(m) and their
corresponding hypothesis testing as H(1), ..., H(m).
2. For a given level q, let k be the largest i such that P(i) ≤ imq.
3. Reject all H(i), i = 1, ..., k.
This procedure controls the FDR at level q when those m tests are independent and
also in various scenarios of dependence.
Besides these methods, other control procedures have also been introduced for gene
expression data(Benjamini et al., 2000; Fernando et al., 2004; Benjamini et al., 2006).
Fold Change
A fold change is a measurement to describe how much a quantity changes going from
an initial to a final value. When speaking of the fold change of a gene, the standard
definition is( Witten et al., 2007)
FCi =
xi.
yi.
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where xij and yij are the raw gene expressions for gene i in replicate j in treatment
group and control group. And a value greater than 1 indicates an increase in gene
expression and a value smaller than 1 means a decrease in gene expression. Much like
p-values, there are some cutoff rules to help with picking up DE genes(Dalman et al.,
2012). And methods which use both p-values and fold changes to identify significant
genes have also been developed(Peart et al., 2005; Patterson et al., 2006; Huggins et
al., 2008; Mccarthy et al., 2009).
p-value histogram
In gene studies, after all the p-values are obtained, drawing a p-value histogram is
a good way to see if any problems exist in the analysis. What we expect is a right
skewed histogram which indicates that there are some differentially expressed genes.
A uniformly distributed p-value histogram indicates very few, if any, genes are dif-
ferentially expressed. Usually these two shapes do not indicate any violation of the
assumptions of methods applied to the data. If we see a histogram has one or more
humps or it is left skewed, this would suggest an inappropriate statistical method was
used to compute p-values. And in gene expression study, a p-value histogram can
also be used to estimate false discovery rate(Storey and Tibshirani, 2003; Nettleton
et al., 2006)
12
Figure 1.1: Right skewed p-value histogram.
Figure 1.2: Uniformly distributed p-value histogram.
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False discovery rate control(Pounds, 2006), fold change and p-value histogram are all
general ways to deal with p-values in gene expression study. And the challenge here
is NanoString technology has only been used for a few years, therefore studies for the
properties of this kind of data are really rare. Most publications are using normaliza-
tion and statistical approaches for data analysis(Vaes et al., 2014; Lee et al., 2015).
And some particular R packages are also based on normalization and t-test, such as
NanoStriDE( Brumbaugh, 2011) and NanoStringNorm( Waggott, 2012). Our goal is
to build a general statistical model, so existing models developed for other types of
gene expression data could be improved.
For example, linear model(Smyth, 2005; Wettenhall, James M and Smyth, Gordon
K, 2004; Wettenhall et al., 2006), mixture model( Pan et al., 2003) and etc have been
developed for Microarray data. And among these, linear model is a widely used one.
Suppose yij is the log transformed gene expression of gene i in array j(i = 1, ..., n; j =
1, ..., p, p+ 1, ..., p+ q). The first p arrays are controls and the last q arrays are treat-
ments. A general statistical model is
yij = ai + bixj + ij
where xj = 1 for control arrays and xj = 0 for treatment arrays, and ij are random
errors with mean 0. To determine if a gene is differentially expressed, it’s equivalent
to test
H0 : bi = 0 vs H1 : bi 6= 0
Copyright c© Shu Shen, 2016.
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Chapter 2 Linear Model
Our basic idea is to use a linear model to detect DE genes for NanoString data. For
each gene, fit a linear model to the raw data.
yij = α + β1trti + β2posij + β3refij + ij
Let i denote the group type: i = 1 for control groups and i = 2 for treatment groups.
For group i, let j denote the jth sample and j = 1, ..., ni. yij is the corresponding raw
gene expression. Let trt1 indicate control groups and trt2 indicate treatment groups.
Set trt1 = 0 and trt2 = 1. posij is the summation of positive controls for group i
and sample j. refij is the geometric mean of reference genes for group i and sample
j. Assume genes are mutually independent and ij
i.i.d.∼ N(0, σ2). And detecting DE
genes is equivalent to test:
H0 : β1 = 0 vs H1 : β1 6= 0
2.1 Simulated and real data
In order to compare the traditional method ( first normalize the raw data and then
perform two sample t-test) with this linear model, we will use simulated and real data
to check their performances. For simulated data, we’re able to define and control DE
genes and check the accuracy of both methods. For real data, since the true DE genes
are unknown, we will see if the result obtained by linear model will be similar to the
result derived by the traditional method.
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2.1.1 Simulation 1
This simulation is a general one and it’s used to check if the linear model works for
the most common assumption for simulated data. We will generate 48 groups (half
of them are control and the other half are treatment), 6 positive controls, 6 reference
genes and 1000 non-reference genes. Negative controls will not be generated since we
will only perform positive control normalization and reference gene normalization.
1. Simulate N (100, 1) for all positive controls.
2. Simulate N (100, 1) for all reference genes.
3. Fix the number of DE genes to be 250. Simulate N (100, 1) for control groups and
N (µ, 1) for treatment groups. We use µ=100.5, 101 and 102 to see how the results
will differ.
4. Simulate N (100, 1) for the rest genes.
After obtaining the simulated data, compute p-values( significant genes will be iden-
tified by using α = 0.05) for all the genes by using both methods. Repeat this simula-
tion 1000 times and count the number of rejected null hypotheses and false positives.
Calculate the proportions of false positives by using number of false positives
number of rejected null hypotheses
and
denote them as mSFDR for linear model method and nSFDR for normalization
method.
Simulation results:
In the following graphs( from Figure 2.1 to Figure 2.6), here’re some interesting pat-
terns of mSFDR and nSFDR:
1. For each value of µ, the value of mSFDR is quite stable.
2. When µ increases, there is a left shift tendency of mSFDRs which means the linear
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model picks less false positives. And also the range of mSFDRs shrinks.
3. Values of nSFDRs are quite spread out and even when the value of µ increases,
this range shrinks, but it’s still quite large comparing to the linear model result.
4. Comparing the distributions of the number of rejected H0 for both methods, we
can see on average, linear model tends to reject a few more null hypotheses.
Figure 2.1: µ = 100.5.
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Figure 2.2: µ = 100.5, M: model method; N: normalization method
Figure 2.3: µ = 101.
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Figure 2.4: µ = 101, M: model method; N: normalization method
Figure 2.5: µ = 102.
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Figure 2.6: µ = 102, M: model method; N: normalization method
As stated in previous chapter, when there are multiple hypothesis tests( in simula-
tion 1, we perform testing 1000 times), in order to control the FDR, we need to do
some adjustments. Next we will apply Bonferroni adjustment and B-H adjustment
to p-values( here we use the p-values list for µ = 101 as an example) and compare
the results to see how the adjustments work( from Figure 2.7 to Figure 2.9).
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Figure 2.7: µ = 101,un-adjusted p-values.
Figure 2.8: µ = 101,Bonferroni adjusted p-values.
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Figure 2.9: µ = 101,B-H adjusted p-values.
In above three graphs, they still maintain the properties that mSFDRs are stable and
nSFDRs are spreading out within a large range, no matter what p-values are used.
If we only consider the proportion of false positives, Bonferroni adjusted p-values
did the best job. But the price is that way less significant genes were picked out (on
average 41 genes were identified as significant by linear model and 32 by t-test). This
shows how conservative Bonferroni adjustment is.
The ranges of mSFDRs given by B-H adjusted p-values and un-adjusted p-values
are (0, 0.1) and (0.1, 0.2). Therefore, B-H adjustment did a good job in reducing the
proportion of false positives. In order to see if these two kinds of p-values can pick
up enough DE genes, the following graph( Figure 2.10) lists four boxplots for the
numbers of true positives. It reveals that B-H adjusted p-values identifies less true
positives than un-adjusted p-values, but considering the smaller proportion of false
positives, B-H adjustment is still a reasonable.
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Figure 2.10: µ = 101, number of true positives of different methods.
In simulation 1, we generated 1000 genes each time with a high proportion (25%) of
DE genes, the proportion of false discoveries is used as a criteria to see which way
is better. Results show that linear model is more stable and B-H adjusted p-value
can help to reduce the proportion of false discoveries. One thing to note is that in
real NanoString data, although it can test up to 800 genes, usually a data set only
contains 100-200 genes with an unknown proportion of DE genes. And we would like
to know when the numbers of genes and DE genes are limited, which way is more
effective. We will generate 200 genes with 12.5% DE genes and µ = 101 while other
settings stay the same.
The following two graphs( Figure 2.11 and Figure 2.12) show that linear model picks
up more true positives with stable proportion(between 0.1 and 0.4) of false positives.
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Figure 2.11: µ = 101, 200 genes with 12.5% DE genes.
Figure 2.12: number of true positives.
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2.1.2 Simulation 2
Simulation 1 doesn’t take any properties of positive controls and reference genes into
account. Such as for each lane, the values of 6 positive controls are listed in a decreas-
ing order from pos1 to pos6. And besides this, here’s another interesting property of
those values. We know positive controls are at known concentrations: 128 fm, 32 fm,
8 fm, 2 fm, 0.5 fm and 0.125 fm. In those real data set examples, values for 0.5 fm
and 0.125 fm are small and appear random. But for the rest concentrations, expres-
sion of 2 fm is approximately equal to 4*expression of 0.5 fm, expression of 8 fm is
approximately equal to 4*expression of 2 fm, and so on. We would like to include this
property in this new simulation which will make the simulated data closer to real data.
For reference genes, even they are supposed to express uniformly across all the lanes,
but each of them is always expressed at different levels. And the same thing happens
to non-reference genes too.
Although NanoString nCounter platform can measure up to 800 genes, but in real
data, wetypically only have seen about 150-200 genes and the sample size is not as
many as simulation 1. All of these will be considered in this new simulation.
Simulation settings:
12 control groups and 12 treatment groups
1. Positive controls: for each lane,
expression of 0.125 fm=a random number from 1 to 10
expression of 0.5 fm =expression of 0.125 fm + a random number from 1 to 5
expression of 2 fm=4* expression of 0.5 fm + a random number from 1 to 10
expression of 8 fm=4* expression of 2 fm + a random number from 1 to 10
expression of 32 fm=4* expression of 8 fm + a random number from 1 to 100
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expression of 128 fm=4* expression of 32 fm + a random number from 1 to 100
This ensures positive controls are following an increasing pattern as the concentration
increases.
2. Reference genes: They are typically expressed at different levels. We define 4
levels: 1-99, 100-999, 1000-9999, 10000-99999 and randomly assign reference genes
to these levels. Once the levels are determined, generate random numbers from each
level to make them the expressions of that reference gene across all the lanes. This
method will make reference genes look like those in real data, but will not guarantee
each reference gene express uniformly across all the lanes.
3. DE genes: 30 DE genes in total. For each of them, generate a random num-
ber from 1 to 1000 and denote it as µ. Simulate N(µ, 1) for control groups and
N(µ+ k, 1) for treatment groups.
4. Non-DE genes: 170 non-DE genes in total. For each of them, generate a ran-
dom number from 1 to 1000 and denote it as µ
′
. Simulate N(µ
′
, 1) for all the lanes.
5. Compute p-values by using both methods and use 0.05 cutoff. And don’t do
p-value adjustment this time since we only have 200 genes.
Repeat this simulation 1000 times.
Simulation results:
In this simulation, we have a much smaller size of measured genes and also DE genes.
Besides controlling false discoveries, we also want to see how many true positives can
be identified. Instead of using proportions, we this time use counts and the reason is
there are a lot of zeros for the number of rejected H0 for t-test method.
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K=2 Case:
For normalized data with t-test (Figure 2.13), there are two extreme clusters. The
left cluster indicates small number of false positives, but the number of true positives
in this cluster is also limited. The right cluster can pick up 20-30 true positives, but
it also picks over 150 false positives. For linear model (Figure 2.14), the numbers
of false positives are almost always under 20 and the numbers of true positives are
always greater than 20.
Figure 2.13: k=2, normalized data with t-test.
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Figure 2.14: k=2, linear model.
K=1 Case:
For normalized data with t-test (Figure 2.15), two extreme clusters still exist. Com-
paring to the left cluster in Figure 2.13, this left cluster also shrinks to the point
(0, 0). And the right cluster indicates over 150 false positives with almost all the true
positives are picked out. For linear model (Figure 2.16), we can see the number of
false positives are always less than 20 and in most cases, more than 10 true positives
could be picked up (Figure 2.20). Figure 2.18, the distribution of true positives picked
up by t-test, shows in most cases, only less than 3 true positives can be identified.
Therefore, linear model is still much better in this situation.
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Figure 2.15: k=1, normalized data with t-test.
Figure 2.16: k=1, linear model.
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Figure 2.17: k=1, normalized data with
t-test, number of false positives
Figure 2.18: k=1, normalized data with
t-test, number of true positives
Figure 2.19: k=1, linear model, number
of false positives
Figure 2.20: k=1, linear model, number
of true positives
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K=0.5 Case:
For normalized data with t-test (Figure 2.21), two extreme clusters are still there.
Figure 2.23 and figure 2.24 provide the details of these two clusters. We can see the
left cluster indicates less than 25 false positives with less than 5 true positives and
the right cluster indicates over 150 false positives with almost all the true positive.
For linear model (Figure 2.22, 2.25 and 2.26), with less than 20 false positives, the
number of true positives are between 0 and 15. And in most cases, this number will
be greater than 5.
Therefore,when k=0.5, linear model is still a better choice.
Figure 2.21: k=0.5, normalized data with t-test.
31
Figure 2.22: k=0.5, linear model.
Figure 2.23: k=0.5, normalized data with
t-test, number of false positives
Figure 2.24: k=0.5, normalized data with
t-test, number of true positives
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Figure 2.25: k=0.5, linear model, number
of false positives
Figure 2.26: k=0.5, linear model, number
of true positives
To handle the problem of reference genes mentioned before, we will use an ideal situ-
ation: for each of them, assume it has the same expression for all the lanes. Make the
difference(k) between control and treatment to be 2 and 0.5, and compare two meth-
ods by taking a look at the numbers of false positives and true positives. According
to table 2.1 and table 2.2, we could say both methods almost behave the same. This
result shows traditional methods is highly affected by bad reference genes and very
likely to fail in picking out DE genes. The linear model often provides much better
result.
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Table 2.1: k=2, left: normalized data with t-test; right: linear model
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Table 2.2: k=0.5, left: normalized data with t-test; right: linear model
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As the linear models all have the same coefficients pos and ref, we may have a de-
pendency problem. In order to check if this problem exists, under the setting of
simulation 2 with k=1, for a single simulated sample, we pull out the p-values for pos
and ref and use a K-S test to see if they are approximately a uniform distribution on
[0,1]. If a uniform distribution of the p-values is unreasonable, a mixed model may
be needed for the dependency variables. After doing this simulation for 1000 times,
the p-values for all the K-S tests are listed in table 2.3, specifically only 48 K-S tests
for pos variable p-values are less than 0.05 and 50 K-S tests for ref variable p-values
are less than 0.05.
Table 2.3: left: K-S test results for pos; right: K-S test results for ref
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2.1.3 Two Sample Example
In section 2.3.1 and section 2.3.2, we did two different kinds of simulations. And in
this section, we will use a real data set to compare these two methods.
In this data, experiment was taken on 12 mice: half of them were healthy and the
other half had a disease. 185 genes were measured and 6 of them were reference
genes. So the traditional method will be normalized data with two sample t-test and
our linear model will function as described before.
Normalized data with t-test picks out 28 significant genes(with 0.05 cutoff) and none
of the reference genes are significant. P-value histogram(Figure 2.27) has a right-
skewed shape which means t-test works properly.
Figure 2.27: normalized data with
t-test
Figure 2.28: linear model
Linear model picks out 35 significant genes(with 0.05 cutoff) and two of them are
reference genes which are Gapdh and Pgk1. P-value histogram(Figure 2.28) also has
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a right-skewed shape with a better tail: it’s more even and smoother, while the tail
of Figure 2.27 has more bumps.
Comparing both significant gene lists, 19 genes are shared by both lists. And those
two reference genes picked out by linear model suggest a question: are they truely
significant genes? Because ideal reference genes have a property that they don’t vary
much across different treatments and from simulation 2, we do know that bad refer-
ence genes can affect results. Since the choice of reference genes is flexible and we
can remove those having too much variation, therefor we will try to remove Gapdh
and Pgk1( leaving 4 reference genes in the analysis) and see what changes will occur
to the significant genes.
After the removal, normalized data with t-test picks out 38 significant genes(with
0.05 cutoff) and p-value histogram(Figure 2.29) still has a right-skewed shape, but a
much smoother tail. Those 4 reference genes which are used to normalize data are
not identified as significant. If we check the removed two reference genes: p-value of
Pgk1 is 0.012( which is significant) and p-value of Gapdh is 0.165. And comparing
this new list with previous one for t-test, they have 20 genes in common.
Linear model picks out 34 significant genes(with 0.05 cutoff) and p-value histogram(Figure
2.30) shows a right-skewed shape. None of the 4 used reference genes are picked out
and Gapdh( p-value: 0.009) and Pgk1( p-value: 0.003) are still identified as signifi-
cant. These 34 significant genes are all included in previous 35 genes which are picked
out by linear model. And after removal, 27 genes are shared by both methods.
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Figure 2.29: normalized data with
t-test (remove 2 reference genes)
Figure 2.30: linear model (remove 2 refer-
ence genes)
Table 2.4: This table shows the numbers of significant genes before and after removal
before removal after removal shared genes
T-test 28 38 20
Linear model 35 34 34
Shared genes 19 27
Table 2.5: This table shows the significance of Gapdh and Pgk1
before removal after removal
T-test Gapdh>0.05, Pgk1>0.05 Gapdh>0.05, Pgk1<0.05
Linear model Gapdh<0.05, Pgk1<0.05 Gapdh<0.05, Pgk1<0.05
Conclusion:
In this example the linear model found that two of the reference genes were differen-
tially expressed. This caused the normalization method to lose power for detecting
genes that are differentially expressed. Without the linear model, the power of the
study is compromised. With the linear model, more differentially expressed genes are
identified include the two reference genes. If the two differentially expressed reference
genes are removed, the linear model and normalization methods are similar, but the
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problem with the reference genes can only be detected by the linear model method.
Copyright c© Shu Shen, 2016.
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Chapter 3 Asymptotic Properties of a Normalized Test of Control versus
Treatment
In this chapter, we derive the large sample distribution of the normalized test for
differences between control and treated groups. Here we assume that the number of
controls(m1) and the number of treated(m2) tend to∞ at the same rate;i.e. m1m1+m2 →
λ, 0 < λ <∞, as m1,m2 →∞.
Define
Ym1 =

1
m1
m1∑
j=1
pC.j
1
m1
m1∑
j=1
rj
p.j
C
1
m1
m1∑
j=1
gj
rj
C

,
Ym2 =

1
m2
m2∑
j=1
pT.j
1
m2
m2∑
j=1
rj
p.j
T
1
m2
m2∑
j=1
gj
rj
T

,
µC =

µ1
µ2
µC
 ,
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and
µT =

µ4
µ5
µT
 .
From the multivariate CLT for i.i.d random vectors (Serfling(1980) Th 1.9.1B),
√
m1(Ym1 − µC) d−→ N(0,ΣC), as m1 →∞,
where
ΣC = V ar

pC.1
r1
p.1
C
g1
r1
C
 =

V ar(pC.1) E(r
C
1 )− µ1µ2 E(pC.1 g1r1
C)− µ1µC
E(rC1 )− µ1µ2 V ar( r1p.1C) E(
g1
p.1
C)− µ2µC
E(pC.1
g1
r1
C)− µ1µC E( g1p.1
C)− µ2µC V ar(g1r1
C)

,
and
√
m2(Ym2 − µT ) d−→ N(0,ΣT ), as m2 →∞,
where
ΣT = V ar

pT.1
r1
p.1
T
g1
r1
T
 =

V ar(pT.1) E(r
T
1 )− µ4µ5 E(pT.1 g1r1
T )− µ4µT
E(rT1 )− µ4µ5 V ar( r1p.1 T ) E(
g1
p.1
T )− µ5µT
E(pT.1
g1
r1
T )− µ4µT E( g1p.1
T )− µ5µT V ar(g1r1
T )

.
Define
Xn =
√
n


Ym1
Ym2
− µ
 ,
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where
µ =

µC
µT
 .
Lemma 1. Suppose m1
n
→ λ, 0 < λ < 1, where n = m1 +m2,then
Xn
d−→ N(0,Σ), as n→∞, where
Σ =

1
λ
ΣC 0
0 1
1−λΣ
T
 .
Proof. First consider
√
n(Ym1 − µC) =
√
n√
m1
√
m1(Ym1 − µC).
Note that
√
n√
m1
→
√
1
λ
, as n→∞.
And by Serfling(1980) Th 1.9.1B,
√
m1(Ym1 − µC) d−→ N(0,ΣC), as n→∞.
By Slutsky’s Theorem, it follows that
√
n(Ym1 − µC) d−→ N(0,
1
λ
ΣC), as n→∞.
Similarly, we can get
√
n(Ym2 − µT ) d−→ N(0, 11−λΣT ), as n→∞.
Since Ym1 and Ym2 are independent, then
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Xn =
√
n


Ym1
Ym2
− µ
 d−→ N
(
0,

1
λ
ΣC 0
0 1
1−λΣ
T

)
, as n→∞.
Also define
cn =
m1
m1 +m2
µ2 +
m2
m1 +m2
µ5 and c = λµ2 + (1− λ)µ5,
dn =
m1
m1 +m2
µ1 +
m2
m1 +m2
µ4 and d = λµ1 + (1− λ)µ4.
Let MNC be the mean of normalized control groups, that is,
MNC =
p..
n2
×
n∑
j=1
rj
p.j
× 1
m1
m1∑
j=1
gj
rj
C
.
Let MNT be the mean of normalized treatment groups, that is,
MNT =
p..
n2
×
n∑
j=1
rj
p.j
× 1
m2
m2∑
j=1
gj
rj
T
.
Lemma 2. If m1
n
→ λ, 0 < λ < 1, then
MNC =cλµC(
1
m1
∑
pC.j − µ1) + c(1− λ)µC(
1
m2
∑
pT.j − µ4)
+ dλµC(
1
m1
∑ rj
p.j
C − µ2) + d(1− λ)µC( 1
m1
∑ rj
p.j
T − µ5)
+ dc(
1
m1
∑ gj
rj
C − µC) + dncnµC + op(n− 12 ), as n→∞,
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and
MNT =cλµT (
1
m1
∑
pC.j − µ1) + c(1− λ)µT (
1
m2
∑
pT.j − µ4)
+ dλµT (
1
m1
∑ rj
p.j
C − µ2) + d(1− λ)µT ( 1
m1
∑ rj
p.j
T − µ5)
+ dc(
1
m1
∑ gj
rj
T − µT ) + dncnµT + op(n− 12 ), as n→∞.
Proof. Write
Xn =
√
n


y1
y2
y3
y4
y5
y6

− µ

Then, by Lemma 1, Xn
d−→ N(0,Σ). But
MNC =(
m1
m1 +m2
y1 +
m2
m1 +m2
y4)(
m1
m1 +m2
y2 +
m2
m1 +m2
y5)y3
=[
m1
m1 +m2
(y1 − µ1) + m2
m1 +m2
(y4 − µ4) + m1
m1 +m2
µ1 +
m2
m1 +m2
µ4]
×[ m1
m1 +m2
(y2 − µ2) + m2
m1 +m2
(y5 − µ5) + m1
m1 +m2
µ2 +
m2
m1 +m2
µ5]y3
=Rn1Rn2y3 +Rn1cny3 + dnRn2y3 + dncny3,
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where
Rn1 =
m1
m1 +m2
(y1 − µ1) + m2
m1 +m2
(y4 − µ4)
and
Rn2 =
m1
m1 +m2
(y2 − µ2) + m2
m1 +m2
(y5 − µ5).
Note that Rn1Rn2y3 is op(n
− 1
2 ), because
√
nRn1 =
√
n(
m1
m1 +m2
(y1 − µ1) + m2
m1 +m2
(y4 − µ4))
=
√
n
m1
n
(y1 − µ1) +
√
n
m2
n
(y4 − µ4)
=
√
n
√
m1
n
√
m1(y1 − µ1) +
√
n
√
m2
n
√
m2(y4 − µ4)
and
√
m1(y1 − µ1) d−→ N(0, σ21),
√
m2(y4 − µ4) d−→ N(0, σ24),
√
n
√
m1
n
→
√
λ and
√
n
√
m2
n
→ √1− λ, as n→∞.
Since y1 and y4 are independent,
√
nRn1
d−→ N(0, λσ21 + (1− λ)σ24),
and Rn2
p−→ 0, y3 p−→ µC . Therefore, Rn1Rn2y3 = op(n−
1
2 ).
Also, Rn1cny3 = Rn1(cn − c)y3 +Rn1cy3, Rn1(cn − c)y3 is op(n−
1
2 ), because
√
nRn1
d−→ N(0, λσ21 + (1− λ)σ24), cn − c→ 0 and y3 p−→ µC .
dnRn2y3 = (dn − d)Rn2y3 + dRn2y3, (dn − d)Rn2y3 = op(n−
1
2 ).
dncny3 = (dncn−dc)(y3−µC)+dc(y3−µC)+dncnµC ,(dncn−dc)(y3−µC) = op(n− 12 ),
because
dncn − dc→ 0 and
√
n(y3 − µC) d−→ N(0, 1
λ
σ2C).
46
Then
MNC =Rn1cy3 +Rn2dy3 + dc(y3 − µC) + dncnµC + op(n−
1
2 )
=(Rn1c+Rn2d)(y3 − µC) + µC(Rn1c+Rn2d)
+ dc(y3 − µC) + dncnµC + op(n− 12 )
(Rn1c+Rn2d)(y3 − µC) is op(n−
1
2 )
=µC(Rn1c+Rn2d) + dc(y3 − µC) + dncnµC + op(n−
1
2 ),
where
Rn1 =
m1
m1 +m2
(y1 − µ1) + m2
m1 +m2
(y4 − µ4)
=(
m1
m1 +m2
− λ)(y1 − µ1) + ( m2
m1 +m2
− (1− λ))(y4 − µ4)
+ λ(y1 − µ1) + (1− λ)(y4 − µ4)
(
m1
m1 +m2
− λ)(y1 − µ1) is op(n− 12 )
(
m2
m1 +m2
− (1− λ))(y4 − µ4) is op(n− 12 )
=λ(y1 − µ1) + (1− λ)(y4 − µ4) + op(n− 12 ).
Similarly,
Rn2 = λ(y2 − µ2) + (1− λ)(y5 − µ5) + op(n−
1
2 )
and
µC(Rn1c+Rn2d) =µC [cλ(y1 − µ1) + c(1− λ)(y4 − µ4) + c ∗ op(n−
1
2 )
+ dλ(y2 − µ2) + d(1− λ)(y5 − µ5) + d ∗ op(n− 12 )]
=cλµC(y1 − µ1) + c(1− λ)µC(y4 − µ4)
+ dλµC(y2 − µ2) + d(1− λ)µC(y5 − µ5) + op(n− 12 ).
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Then
MNC =cλµC(y1 − µ1) + c(1− λ)µC(y4 − µ4) + dλµC(y2 − µ2)
+ d(1− λ)µC(y5 − µ5) + dc(y3 − µC) + dncnµC + op(n− 12 )
=cλµC(
1
m1
∑
pC.j − µ1) + c(1− λ)µC(
1
m2
∑
pT.j − µ4)
+ dλµC(
1
m1
∑ rj
p.j
C − µ2) + d(1− λ)µC( 1
m1
∑ rj
p.j
T − µ5)
+ dc(
1
m1
∑ gj
rj
C − µC) + dncnµC + op(n− 12 ).
And we can get MNT in a similar way.
The next lemma uses Serfling(1980) Theorem A (page 122), which is given below
Theorem A: Suppose that Xn = (Xn1, ..., Xnk) is AN(µ, b
2
nΣ) with Σ a covariance
matrix and bn → 0. Let g(x) = (g1(x), ...gm(x)), x = (x1, ...xk), be a vector valued
function for which each component function gi(x) is real-valued and has a nonzero
differential gi(µ; t), t = (t1, ...tk), at x = µ. Put
D =
[
∂gi
∂xj
∣∣∣
x=µ
]
m×k
.
Then
g(Xn) is AN(g(µ), b
2
nDΣD
′
).
Let
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Yn =

1
m1
∑
pC.j − µ1
1
m1
∑ rj
p.j
C − µ2
1
m1
∑ gj
rj
C − µC
1
m2
∑
pT.j − µ4
1
m2
∑ rj
p.j
T − µ5
1
m2
∑ gj
rj
T − µT

=

y1
y2
y3
y4
y5
y6

,
g1(Y ) =g1(y1, ..., y6)
=cλµCy1 + c(1− λ)µCy4 + dλµCy2 + d(1− λ)µCy5 + dcy3,
and
g2(Y ) =g2(y1, ..., y6)
=cλµTy1 + c(1− λ)µTy4 + dλµTy2 + d(1− λ)µTy5 + dcy6.
Lemma 3. If m1
n
→ λ, 0 < λ < 1, as n→∞, then
√
n

g1(Yn)
g2(Yn)
 d−→ N(0, DΣD′), as n→∞, where
D =
(
∂gi
∂xj
∣∣∣∣
x=µ
)
=

cλµC dλµC dc c(1− λ)µC d(1− λ)µC 0
cλµT dλµT 0 c(1− λ)µT d(1− λ)µT dc
 .
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Proof. From Lemma 1, we have
√
nYn =
√
n

y1
y2
y3
y4
y5
y6

d−→ N(0,Σ),
which is Yn is AN(0, n
−1Σ).
Let
g(Y ) =

g1(Y )
g2(Y )
 .
According to Theorem A, g(Yn) is AN(0, n
−1DΣD
′
), where
D =
(
∂gi
∂xj
∣∣∣∣
x=µ
)
=

cλµC dλµC dc c(1− λ)µC d(1− λ)µC 0
cλµT dλµT 0 c(1− λ)µT d(1− λ)µT dc
 .
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That is
√
n

g1(Yn)
g2(Yn)
 d−→ N(0, DΣD′), as n→∞.
Lemma 4. As n→∞,
MNC −MNT − (dncn(µC − µT )) is AN(0, 1
n
vDΣD
′
v
′
), where
v = (1,−1) and
D =

cλµC dλµC dc c(1− λ)µC d(1− λ)µC 0
cλµT dλµT 0 c(1− λ)µT d(1− λ)µT dc
 .
Proof. Let G(Z) = z1 − z2,
Z =

z1
z2
 .
Since
g(Yn) =

g1(Yn)
g2(Yn)
 isAN(0, n−1DΣD′),
then according to Theorem A
G


g1(Yn)
g2(Yn)

 = g1(Yn)− g2(Yn) is AN(0, n−1vDΣD′v′),
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which is
√
n(g1(Yn)− g2(Yn)) d−→ N(0, vDΣD′v′), where v = (1,−1) and D takes the
value from Lemma 3.
Note that from Lemma 2
√
n(MNC −MNT ) =
√
n(g1(Yn)− g2(Yn) + dncn(µC − µT ) + op(n− 12 )),
and we have
√
n ∗ op(n− 12 ) p−→ 0.
This implies
MNC −MNT − (dncn(µC − µT )) d−→ N(0, 1
n
vDΣD
′
v
′
).
Copyright c© Shu Shen, 2016.
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Chapter 4 Conclusions and Future Work
This dissertation is devoted to the analysis of NanoString nCounter data via a linear
regression model. Specifically, we introduce this new type of gene expression data
at the very beginning and then present two types of normalization methods. After
this, we carefully examine the entire normalization process and find out its potential
problems which could affect the statistical analysis results. And then we propose our
linear regression method which is stable and effective.
This linear model is developed to discover differentially expressed genes. In order
to compare it with traditional method, we simulate two kinds of data and use the
proportion of false discoveries as the rule to check which method is better. And in
both conditions, the linear model always has more stable and trustable results. Be-
sides simulated data, we also use a real data set to compare the two methods, the
genes lists identified by picked out by the traditional method are highly influenced
by reference genes while linear model is much less sensitive to them.
Our theoretical research is about the asymptotic properties of the normalized test
of control versus Treatment. The results reveal us why the traditional normalization
method fails in some cases. Future work could consider asymptotic properties for
more complex experimental designs.
Copyright c© Shu Shen, 2016.
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Appendices
A. R code for Simulation 1
### n1: number of control groups
### n2: number of treatment groups
### mu: mean of DE treatment
### 250 DE genes and 750 non-DE genes
### 6 positive control, 6 reference genes
simulation1<-function(n1,n2,mu ){
pos<-matrix((rnorm((n1+n2)*6, mean = 100, sd = 1)),nrow=6)
rownames(pos) <- paste("pos",1:6)
ref<-matrix((rnorm((n1+n2)*6, mean = 100, sd = 1)),nrow=6)
rownames(ref) <- paste("ref",1:6)
dectrl<-matrix((rnorm(n1*250, mean = 100, sd = 1)),nrow=250)
detrt<-matrix((rnorm(n2*250, mean = mu, sd = 1)),nrow=250)
de<-cbind(dectrl,detrt)
nonde<-matrix((rnorm((n1+n2)*750, mean = 100, sd = 1)),nrow=750)
gene<-rbind(de,nonde)
rownames(gene) <- paste("gene",1:1000)
design<-c(rep(0, n1), rep(1, n2))
return(list(pos=pos, ref=ref, gene=gene, design=design))
}
###########################################################################
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res<-matrix(0, 1000, 4) ###simulate this data frame 1000 times
for (j in 1:1000){
s<-simulation1(24, 24, 100.5)
pos<-s$pos
ref<-s$ref
gene<-s$gene
design<-s$design
possum<-apply(pos, 2,sum)
geomean = function(x){prod(x)^(1/length(x))}
refgeomean<- apply(ref,2,geomean)
scalar<-mean(possum)* mean(refgeomean/possum)/ refgeomean
scalar<-matrix(scalar, nrow=1)
scalarmatrix= matrix(rep(scalar,1000),nrow=1000,byrow=TRUE)
normalizedgene<-gene* scalarmatrix
mpvalue<-rep(0,1000); ###compute p-values by using linear model
for (i in 1:1000){
data<-data.frame(gene=gene[i,], trt=design,pos=possum,ref=refgeomean)
fit<- lm(gene~trt+pos+ref,data=data)
mpvalue[i]<-summary(fit)$coefficients[2,4];
}
mR=length(which(mpvalue<0.05)) ### number of rejected H0
mV=length(which(mpvalue[251:1000]<0.05)) ### number of false positives
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npvalue<-rep(0,1000); ###compute p-values by using normalized data
for (i in 1:1000){
data<-data.frame(ctrl= normalizedgene [i,1:24], trt= normalizedgene [i,25:48])
npvalue[i]<- t.test(data$ctrl, data$trt)$p.value
}
nR=length(which(npvalue<0.05)) ### number of rejected H0
nV=length(which(npvalue[251:1000]<0.05)) ### number of false positives
res[j,]=c(mR, mV, nR, nV)
}
mSFDR=res[,2]/res[,1]
nSFDR=res[,4]/res[,3]
plot(mSFDR, nSFDR, asp=1)
abline(0,1,col="red")
boxplot(res[,1], res[,3], names=c("number of rejected H0 of M",
"number of rejected H0 of N"))
###compute "bonferroni" and "BH" adjusted p-value for both methods
bonfmpvalue=p.adjust(mpvalue, "bonferroni")
bonfmR=length(which(bonfmpvalue<0.05)) ### number of rejected H0
bonfmV=length(which(bonfmpvalue[251:1000]<0.05)) ### number of false positives
bhmpvalue=p.adjust(mpvalue, "BH")
bhmR=length(which(bhmpvalue<0.05)) ### number of rejected H0
56
bhmV=length(which(bhmpvalue[251:1000]<0.05)) ### number of false positives
bonfnpvalue=p.adjust(npvalue, "bonferroni")
bonfnR=length(which(bonfnpvalue<0.05)) ### number of rejected H0
bonfnV=length(which(bonfnpvalue[251:1000]<0.05)) ### number of false positives
bhnpvalue=p.adjust(npvalue, "BH")
bhnR=length(which(bhnpvalue<0.05)) ### number of rejected H0
bhnV=length(which(bhnpvalue[251:1000]<0.05)) ### number of false positives
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B. R code for Simulation 2
### n1: number of control groups
### n2: number of treatment groups
### 30 DE genes, 170 non-DE genes
### k: the shift between control and treatment for DE genes
simulation2<-function(n1,n2, k){
###generate positive controls, use their concentration property
###and make an increasing pattern
x6<-sample(1:10, n1+n2,replace=T)
x5<-x6 +sample(1:5, n1+n2,replace=T)
x4<-4*x5+ sample(0:10, n1+n2,replace=T)
x3<-4*x4+ sample(0:10, n1+n2,replace=T)
x2<-4*x3+ sample(0:100, n1+n2,replace=T)
x1<-4*x2+ sample(0:100, n1+n2,replace=T)
pos<-rbind(x1, x2, x3, x4, x5, x6)
rownames(pos) <- paste("pos",1:6)
###reference genes are always expressed at different levels, set
###them as: 1-99, 100-999, 1000-9999, 10000-99999
refcar<-rep(0,6);
for (i in 1:6){
x<-sample(1:4, 1,replace=T)
refcar[i]<-x
}
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ref<-matrix(0, 6, n1+n2)
for (j in 1:6){
if( refcar[j]==1)
{ ref[j, ]= matrix(sample(1:99, n1+n2,replace=T), nrow=1)}
else if (refcar[j]==2)
{ ref[j, ]= matrix(sample(100:999, n1+n2,replace=T), nrow=1)}
else if (refcar[j]==3)
{ ref[j, ]= matrix(sample(1000:9999,n1+n2,replace=T), nrow=1)}
else {ref[j, ]= matrix(sample(10000:99999,n1+n2,replace=T), nrow=1)}
}
rownames(ref) <- paste("ref",1:6)
###generate DE genes
de<-matrix(0, 30, n1+n2)
for (t in 1:30){
mu1<-sample(1:1000, 1,replace=T)
de[t, 1:n1]<-rnorm(n1, mu1, sd=1)
de[t, n1+1: n2]<-rnorm(n2, mu1+k, sd=1)
}
###generate non-DE genes
nonde<-matrix(0, 170, n1+n2)
for (h in 1:170){
mu2<-sample(1:1000, 1,replace=T)
nonde[h, ]<-rnorm(n1+n2, mu2, sd=1)
}
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gene<-rbind(de,nonde)
rownames(gene) <- paste("gene",1:200)
design<-c(rep(0, n1), rep(1, n2))
return(list(pos=pos, ref=ref, gene=gene, design=design))
}
res<-matrix(0, 1000, 4)
for (j in 1:1000){
s<-simulation2(12, 12, 2)
pos<-s$pos
ref<-s$ref
gene<-s$gene
design<-s$design
possum<-apply(pos, 2,sum)
geomean = function(x){prod(x)^(1/length(x))}
refgeomean<- apply(ref,2,geomean)
scalar<-mean(possum)* mean(refgeomean/possum)/ refgeomean
scalar<-matrix(scalar, nrow=1)
scalarmatrix= matrix(rep(scalar,200),nrow=200,byrow=TRUE)
normalizedgene<-gene* scalarmatrix
mpvalue<-rep(0,200);
for (i in 1:200){
data<-data.frame(gene=gene[i,], trt=design,pos=possum,ref=refgeomean)
fit<- lm(gene~trt+pos+ref,data=data)
mpvalue[i]<-summary(fit)$coefficients[2,4];
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}mR=length(which(mpvalue<0.05)) ### number of rejected H0
mV=length(which(mpvalue[31:200]<0.05)) ### number of false positives
npvalue<-rep(0,200);
for (i in 1:200){
data<-data.frame(ctrl= normalizedgene [i,1:12], trt= normalizedgene [i,13:24])
npvalue[i]<- t.test(data$ctrl, data$trt)$p.value
}
nR=length(which(npvalue<0.05)) ### number of rejected H0
nV=length(which(npvalue[31:200]<0.05)) ### number of false positives
res[j,]=c(mR, mV, nR, nV)
}
mR<-res[,1]
mV<-res[,2]
nR<-res[,3]
nV<-res[,4]
plot(nV, nR-nV, xlab ="# of false positives", ylab ="# of true positives",asp=1)
plot(mV, mR-mV, xlab ="# of false positives", ylab ="# of true positives",asp=1)
Copyright c© Shu Shen, 2016.
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